China-based Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553) has announced its its subsidiaries Seacross Pharma (Europe) and Seacross Pharmaceuticals Ltd. receiving a series of marketing approvals for its products in Italy, Portugal, and Saudi Arabia. The approved products include valproate concentrated solution, zoledronic acid, teicoplanin, and plerixafor.
Valproate Concentrated Solution
Valproate, approved in Italy, serves as an antiepileptic substitute for oral dosage forms in adults and children when oral forms are temporarily unavailable. It is primarily used for treating generalized seizures, including absence seizures, muscle spasms, tonic-clonic seizures, focal seizures, and secondary generalized seizures.
Zoledronic Acid
Also approved in Italy, zoledronic acid is indicated for treating osteoporosis in postmenopausal women and adult men, osteoporosis induced by long-term glucocorticoid therapy in these groups, and Paget’s bone disease (osteitis deformans) in adults.
Teicoplanin
Teicoplanin, which gained marketing approval in Portugal, is used to treat extraintestinal infections in adults and children. These include complex skin and soft tissue infections, bone and joint infections, acquired pneumonia, complications of urinary tract infections, infective endocarditis, peritonitis related to continuous flow peritoneal dialysis, and bacteremia associated with the aforementioned symptoms. Additionally, it can be used for treating diarrhea and colitis related to Clostridium difficile.
Plerixafor
Plerixafor is now registered in Saudi Arabia. It is used in combination with granulocyte colony-stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) into the peripheral blood of patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) for HSC collection and autologous transplantation.-Fineline Info & Tech
Leave a Reply